At baseline and after 1 week of therapy , fecal microbiota composition ( Human Intestinal Tract Chip phylogenetic microarray ) , fecal and plasma bile acid concentrations as well as insulin sensitivity ( hyperinsulinemic euglycemic clamp using [ 6,6 - ( 2 ) H2 ] - glucose tracer ) were measured .